Exclusive Video Q&A With Sijmen de Vries, CEO of Pharming MarketWatch (press release) ... purifies and formulates recombinant human proteins using its transgenic technology platform for therapeutic indications in Hereditary Angioedema, Transplant Rejection, Blood Coagulation Disorders and Ischemic Reperfusion Injury. |
